US20070179300A1 - Process for preparing thiazole derivative and the intermediate compounds for preparing the same - Google Patents

Process for preparing thiazole derivative and the intermediate compounds for preparing the same Download PDF

Info

Publication number
US20070179300A1
US20070179300A1 US11/730,658 US73065807A US2007179300A1 US 20070179300 A1 US20070179300 A1 US 20070179300A1 US 73065807 A US73065807 A US 73065807A US 2007179300 A1 US2007179300 A1 US 2007179300A1
Authority
US
United States
Prior art keywords
formula
alkyl
compound
compounds
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/730,658
Inventor
Heonjoong Kang
Jungyeob Ham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seoul National University Industry Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/730,658 priority Critical patent/US20070179300A1/en
Publication of US20070179300A1 publication Critical patent/US20070179300A1/en
Assigned to SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION reassignment SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAM, JUNGYEOB, KANG, HEONJOONG
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for preparing thiazole derivative of formula (XI), that activates the delta subtype of the human Proxisome Proliferator Activated Receptor (hPPAR ⁇ ), and also relates to the compounds of formula (VI), (VII), (VIII) and (IX), intermediate compounds for preparation of the above compound of formula (XI).
  • GW501516 2- ⁇ 2-methyl-4-[( ⁇ 4-metyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl ⁇ methyl)sulfonyl]phenoxy ⁇ acetic acid (hereinafter, called “GW501516”) among thiazole derivatives of formula (XI) was excellent in treating obesity in animal models ( Cell 2003, 113, 159), and proved its effectiveness in cardiovascular disease by increasing high density lipoprotein (HDL) and decreasing low density lipoprotein (LDL) effectively in the animal experiment ( Proc. Natl. Acad. USA 2001, 98, 5306) and in clinical trial. And the process for preparation-of the said substance has been disclosed in WO 01/00603 A1 and Bioorg. Med.
  • HDL high density lipoprotein
  • LDL low density lipoprotein
  • the compound (13) of GW501516 can be prepared by introducing ethyl acetate group to o-cresol (14), reacting the resulted compound (15) with sulfonyl chloride, reducing the resulted compound (16) with tin (Sn) under acidic condition to form ethyl (4-mercapto-2-methyl phenoxy)acetate (17), reacting it with 5-chloromethyl -4-methyl-2-(4-trifluoromethyl phenyl)thiazole (11) together with an excessive cesium carbonate to obtain the ethyl ester intermediate (18) of GW501516, and deprotecting the ester group of the intermediate compound with 1 N lithium hydroxide.
  • n is an integer of 0 to 5
  • R 2 represents a hydrogen atom, fluorine atom, chlorine atom, —(C 1 -C 4 ) alkyl, —O(C 1 -C 4 ) alkyl, —S(C 1 -C 4 ) alkyl, or —N(C 1 -C 4 alkyl) 2 group,
  • R 3 represents a protecting group having a tetrahydropyranyl, —(C 1 -C 4 ) alkyl, allyl, or silyl group such as alkylsilyl, alkylarylsilyl,
  • R 4 represents a —(C 1 -C 4 ) alkyl group
  • X 1 represents a halogen atom
  • X 2 represents a halogen atom, or leaving group easily displaced by nucleophiles
  • M represents a lithium ion or magnesium halide (Cl, Br, or I).
  • An object of the present invention is to provide a process for preparing compounds of formula (XI) in high yield in a short period, via unstable intermediate compounds without separation step in the reaction.
  • the present invention also provides a process for preparing compounds of formula (II), which comprises by reacting compounds of formula (I) with alkyl 2-chloroacetoacetate.
  • the present invention further provides a process for preparing compounds of formula (III), which comprises by reducing the ester group of compounds of formula (II).
  • the present invention further provides a process for preparing compounds of formula (IV), which comprises by introducing a leaving group to compounds of formula (III).
  • the present invention further provides a process for preparing compounds of formula (VI), which comprises by reacting compounds of formula (V) with a phenol protecting group.
  • the present invention further provides a process for preparing compounds of formula (VIII), which comprises by reacting compounds of formula (VI) with metallic or organometallic reagents and sulfur to form compounds of formula (VII), and reacting them with compounds of formula (IV) without a specific organic or inorganic base.
  • the present invention further provides a process for preparing compounds of formula (IX), which comprises by eliminating the protecting group of phenol of compounds of formula (VIII).
  • the present invention further provides a process for preparing compounds of formula (X), which comprises by reacting compounds of formula (IX) with alkyl haloacetate in the presence of organic or inorganic base.
  • the present invention further provides a process for preparing compounds of formula (XI), which comprises by subjecting the ester compounds of formula (X) to hydrolyze.
  • the present invention further provides processes for the novel compounds of formula (VI), (VII), (VIII), and (IX), each of which useful as intermediate compounds for preparation of the final products of the present invention.
  • R 1 represents hydrogen atom, CF 3 , or halogen atom, and the number (n) of the substituent is 0 to 5 of the same or different one.
  • R 2 stands for hydrogen atom, fluorine atom, chlorine atom, —O-alkyl, —S-alkyl, or —N-(alkyl) 2 (alkyl group having 1 to 4 carbon atoms).
  • the position of each substituent is ortho- or meta- to the phenol group, and the number of substituent is 1 or 2.
  • R 3 is a protecting group, and includes a tetrahydropyranyl, alkyl or allyl group having 1 to 4 carbon atoms, or silyl group such as trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl.
  • Preferred examples of the protecting groups among them include tert-butyl, tetrahydropyranyl and silylated groups.
  • R 4 is a protecting group, and examples thereof include alkyl having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, n-butyl, and tert-butyl group. Of these, methyl, ethyl, and propyl are preferred.
  • Example of the halogen atom represented by X 1 includes a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • X 2 represents a leaving group, which can be easily displaced by metal thiolate in nucleophilic substitution reaction.
  • halogen atom means a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • M represents a lithium ion or magnesium halide (Cl, Br, or I).
  • Compounds of formula (II) can be prepared by reacting compounds of formula (I) with ethyl or methyl 2-chloroacetoacetate in a solvent.
  • Suitable solvents usable in this reaction include alcohols such as methanol, ethanol, propanol, and butanol; and ethers such as diethyl ether, tetrahydrofuran, and 1,4-dioxane. Of these, ethanol or tetrahydrofuran is preferred as a solvent.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct the reaction at 25 to 150° C. for 6 hours to 1 day, more preferably 60 to 120° C. within 16 hours.
  • aluminum hydrides such as lithium aluminum hydride, and diiusobutylaluminum hydride, and boron hydrides such as sodium borohydride and lithium borohydride can be given.
  • lithium aluminum hydride and diissobutylaluminum hydride are preferred.
  • diethyl ether, tetrahydrofuran, and dichloromethane can be given, with preferably, dichloromethane.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct the reaction at ⁇ 100 to 60° C. for 30 minutes to 6 hours, more preferably ⁇ 78 to 25° C. within 2 hours.
  • Compounds of formula (IV) can be prepared by subjecting halogenation reaction on compounds of formula (III), or reacting compounds of formula (III) with methanesulfonyl chloride orp-toluene sulfonyl chloride in a solvent.
  • Suitable solvents usable in this include N,N-dimethylformamide, diethyl ether, tetrahydrofuran, tetrachloromethane, chloroform, dichloromethane, and pyridine. Of these, dichloromethane for halogenation reaction, and pyridine for methanesulfonate or p-toluenesulfonate reaction respectively are preferred.
  • Suitable reagents for halogenation reaction to the alcohol moiety include triphenylphosphine (TPP) with N-chlorosuccinimide (NCS), triphenylphosphine with chlorine gas, triphenylphosphine with tetrachloromethane(CCl 4 ), phosphorus pentachloride (PCl 5 ), thionylchloride (SOCl 2 ), and methanesulfonyl chloride (MeSO 2 Cl) for introduction of chlorine atom; triphenylphosphine with N-bromosuccinimide (NBS), triphenylphosphine with bromine gas, triphenylphosphine with tetrabromomethane (CBr 4 ), phosphorus pentabromide (PBr 5 ), and thionyl bromide (SOBr 2 ) for introduction of bromine atom; triphenylphosphine with N-iodosuccine imide, trip
  • introduction of iodine atom can be carried out by substituting chloro- or bromocompounds of formula (IV) with sodium iodide(NaI) in acetone, so-called halogen-iodine substitution method.
  • the preferred leaving group is chlorine or bromine atom
  • the preferred reagent for this reaction is triphenylphosphine with N-chlorosuccinimide or N-bromosuccinimide.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at ⁇ 10 to 40° C. for 30 minutes to 1 day, more preferably 10 to 25° C. within 2 hours.
  • Compounds of formula (VI) can be prepared by reacting compounds of formula (V) with conventional compounds for protecting phenol group in the presence of a base in a solvent.
  • Suitable solvents usable in this reaction include N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, acetone, ethyl acetate, tetrachloromethane, chloroform, and dichloromethane as aprotic polar solvents; tetrahydrofuran, 1,4-dioxane, dimethoxy ethane, and diethylene glycol dimethyl ether as ethers; and benzene, toluene, and xylene as aromatic hydrocarbons.
  • an aprotic polar solvent is preferred, with N, N-dimethylformamide, chloroform, or dichloromethane being particularly preferred.
  • Suitable base usable for reacting silyl protecting group with phenol include amines such as pyridine, triethylamine, imidazole, and N, N-dimethylaminopyridine.
  • Suitable bases usable for reacting aryl ether protecting group with phenol include sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate. As the preferred bases among the above, imidazole and potassium carbonate can be given.
  • Tetrahydropyranyl (THP) protection on the phenol group can be achieved by reacting 3,4-dihydro-2H-pyran with alkyl or aryl triphenylphosphonium bromide.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at ⁇ 10 to 80° C. for 1 hour to 1 day, more preferably 0 to 25° C. within 4 hours.
  • Compounds of formula (VIII) can be prepared by reacting intermediate compounds of formula (VII), without separation, with compounds of formula (IV) in an anhydrous solvent.
  • Suitable anhydrous solvents usable in this reaction include diethyl ether, tetrahydrofuran, hexane, and heptane. These solvents may be used either singly or in combination of two. Diethyl ether, tetrahydrofuran, and a mixed solvent of diethyl ether with tetrahydrofuran are particularly preferred.
  • lithium metal and magnesium metal can be given, and as organometallic reagents, n-butyllithium, sec-butyllithium, and tert-butyllithium can be used. Of these, organometallic reagents are preferred, with n-butyllithium and tert-butyllithium being particularly preferred.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at ⁇ 100 to 25° C. for 30 minutes to 1 day, more preferably in the step of sulfur introduction at ⁇ 78° C., later raising the reaction temperature up to 25° C. for 1 hour after introduction of compounds of formula (IV) into the reaction mixture.
  • Compounds of formula (IX) can be prepared by eliminating the phenol-protecting group of compounds of formula (VIII) in a solvent.
  • Suitable solvents usable in this reaction include N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, acetone, ethyl acetate, tetrachloromethane, chloroform, and dichloromethane as polar solvents; tetrahydrofuran, 1,4-dioxane, dimethoxy ethane, and diethylene glycol dimethyl ether as ethers; and benzene, toluene, and xylene as aromatic hydrocarbons. Of these, tetrahydrofuran is particularly preferred.
  • Suitable reagents for elimination of the protecting groups of methyl, ethyl, tert-butyl, benzyl, allyl on the phenol group include a Lewis acid such as trimethylsilyliodide, ethane thioalcohol, lithium iodide, aluminum bromide, aluminum chloride, boron triiodide, and trifluoroacetic acid; suitable reagents for elimination of silylated protecting groups such as trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, tert-butyldimethylsilyl include tetrabutylammonium fluoride, hydrochloric acid, hydrobromic acid, hydroiodic acid, and potassium fluoride. Of these, tetrabutylammonium fluoride is preferred for eliminating the silyl-protecting group on the phenol.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at 0 to 120° C. for 30 minutes to 1 day, more preferably 10 to 25° C. within 2 hours.
  • Compounds of formula (X) can be prepared by reacting compounds of formula (IX) with alkyl halogen acetates in the presence of a base in a solvent.
  • the alkyl halogen acetates are commercially available or can be synthesized by known methods in the art.
  • the alkyl group and halogen therein include methyl, ethyl, tert-butyl and a chlorine atom, bromine atom, and iodine atom, respectively.
  • the most preferred one among the alkyl halogen acetates is methyl (or ethyl) chloro (or bromo)acetate.
  • Suitable solvents usable in this reaction include N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, and acetone, with acetone being particularly preferred.
  • bases used regardless of basicity, inasmuch as the base does not affect the reaction.
  • Suitable bases include sodium hydride, lithium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, and potassium bicarbonate.
  • alkali metal hydride or alkali metal carbonate is preferred, with potassium carbonate being particularly preferred.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at ⁇ 10 to 120° C. for 30 minutes to 1 day, more preferably 0 to 25 ° C. within 4 hours.
  • Compounds of formula (XI) can be prepared by subjecting hydrolysis of the carboxylic ester of compounds of formula (X) in the presence of a water-soluble inorganic base and alcohol solvent.
  • Suitable solvents usable in this reaction include methanol, ethanol, and water miscible organic solvents.
  • alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, or potassium hydroxide
  • 1 to 3 N sodium hydroxide is preferred.
  • reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at ⁇ 10 to 80° C. for 10 minutes to 3 hours, more preferably 0 to 25° C. for 30 minutes to 1 hour.
  • Methyl 4-methyl-2-[4-(trifluoromethyl)phenyl]]thiazole-5-carboxylate (20.0 g, 66.4 mmol) obtained from Example 1 was dissolved in anhydrous dichloromethane (500 Ml) under nitrogen atmosphere, and the reaction mixture was cooled to ⁇ 78° C.
  • Diisobutyl aluminum hydride (DIBAL-H, 166 Ml, 1.0 M hexane solution, 2.5 eq.) was slowly added to the solution for 30 minutes, and the mixture was reacted for another 30 minutes at the same temperature. Subsequently, the temperature was raised to ⁇ 10° C. and reacted for 30 minutes.
  • [4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (15.0 g, 55.0 mmol) obtained from Example 2 was dissolved in anhydrous dichloromethane (300 Ml), and then triphenylphosphine (TPP, 5.7 g, 60.0 mmol, 1.1 eq.) and tetrabromomethane (20.0 g, 60.0 mmol, 1.1 eq.) were added to the mixture sequentially at room temperature. After 1 hour, the solvent was evaporated from the reaction mixture under reduced pressure.
  • TPP triphenylphosphine
  • tetrabromomethane 20.0 g, 60.0 mmol, 1.1 eq.
  • TPP triphenylphosphine
  • [4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (10.0 g, 36.6 mmol) obtained from Example 2 was dissolved in anhydrous dichloromethane (250 Ml) and then triphenylphosphine (TPP, 11.5 g, 44.0 mmol, 1.2 eq.) and N-chlorosuccinimide (5.86 g, 44.0 mmol, 1.2 eq.) were added to the mixture at room temperature. After completion of the reaction, the solvent was evaporated under reduced pressure.
  • TPP triphenylphosphine
  • N-chlorosuccinimide 5.86 g, 44.0 mmol, 1.2 eq.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a process for preparing thiazole derivatives of formula (XI), that activate the delta subtype of the human Peroxisome Proliferator Activated Receptor (hPPARδ), and also provides processes for compounds of formula (VI), (VII), (VIII) and (IX), intermediate compounds for preparation of the above compounds of formula (XI).

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of Application No. 10/513,408, filed Nov. 4, 2004, now allowed; which is a U.S. national stage of Application No. PCT/KR2003/000877, filed May 1, 2003; the contents of which are incorporated by reference herein.
  • TECHNICAL FIELD
  • The present invention relates to a process for preparing thiazole derivative of formula (XI), that activates the delta subtype of the human Proxisome Proliferator Activated Receptor (hPPARδ), and also relates to the compounds of formula (VI), (VII), (VIII) and (IX), intermediate compounds for preparation of the above compound of formula (XI).
  • Background Art
  • Especially 2-{2-methyl-4-[({4-metyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl)sulfonyl]phenoxy}acetic acid (hereinafter, called “GW501516”) among thiazole derivatives of formula (XI) was excellent in treating obesity in animal models (Cell 2003, 113, 159), and proved its effectiveness in cardiovascular disease by increasing high density lipoprotein (HDL) and decreasing low density lipoprotein (LDL) effectively in the animal experiment (Proc. Natl. Acad. USA 2001, 98, 5306) and in clinical trial. And the process for preparation-of the said substance has been disclosed in WO 01/00603 A1 and Bioorg. Med. Chem. Lett. 2003, 13, 1517, in which GW501516 (13) was prepared, as shown in the following scheme (1). Methyl (4-mercapto-3-methylphenoxy)acetate (7), synthesized from the starting material, 4′-hydroxy-3′-methylacetophenone (1), via six steps, was coupled to 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)thiazole (11), which was prepared from 4-(trifluoromethyl)thiobenzamide (8) via three steps, in the presence of excessive cesium carbonate to obtain the methyl ester (12) of GW501516, and then treating the ester with 1 N lithium hydroxide to give GW501516.
    Figure US20070179300A1-20070802-C00001
  • As an alternative method of synthesizing GW501516, it is disclosed, as illustrated in the following scheme (2), that the compound (13) of GW501516 can be prepared by introducing ethyl acetate group to o-cresol (14), reacting the resulted compound (15) with sulfonyl chloride, reducing the resulted compound (16) with tin (Sn) under acidic condition to form ethyl (4-mercapto-2-methyl phenoxy)acetate (17), reacting it with 5-chloromethyl -4-methyl-2-(4-trifluoromethyl phenyl)thiazole (11) together with an excessive cesium carbonate to obtain the ethyl ester intermediate (18) of GW501516, and deprotecting the ester group of the intermediate compound with 1 N lithium hydroxide.
    Figure US20070179300A1-20070802-C00002
  • Although the above compound (13) was known to have excellent efficacy in treating obesity in animal models and in treating disease states associated with cholesterol metabolism in clinical trials, the manufacturing method thereof was not satisfactory, thereby being not cost-effective. That is to say,
      • 1) The manufacturing method of reaction scheme (1) consists of 12 steps, and the total yield thereof is as low as 2%. So, it is not proper to be applied to the industry, due to its extreme low production yield.
      • 2) The manufacturing process according to the reaction scheme (1) includes three refluxing steps at elevated temperature for 16 hours, which takes long time to obtain the final product.
      • 3) Tin (Sn) powder used in reaction scheme (2) is very unstable to the moisture, and moreover, it is a combustible metal, thereby being very dangerous to adopt it in industrial scale.
      • 4) An excessive tin (Sn) powder used in the reaction scheme (2) may lead to pollution of the environment.
      • 5) A separated another step for reacting compound (11) with compound (7) or compound (17) in the reaction scheme (1) or (2) is required, and also an excess amount of cesium carbonate, which is not common inorganic base, is used, and also the reaction time is comparatively long.
      • 6) The hydrolysis steps of methyl or ethyl ester using 1 N lithium hydroxide in reaction scheme (1) or (2) requires a long reaction time, about 16 hours, of which yield is as low as 60%.
      • 7) Methyl or ethyl (4-mercapto-2-methylphenoxy)acetate (7) or (17) obtained as an intermediate compound in the reaction scheme (1) or (2) is unstable, so the respective compound can be easily changed to disulfides, which results in lowering the total reaction yield.
  • Under the circumstance, the novel process for preparing the above compound with easiness and low cost has been demanded in the art.
  • DISCLOSURE OF THE INVENTION
  • In view of the above situation, the inventors of the present invention have conducted extensive studies on novel processes for preparing compounds of the following formula (XI). As a result, the inventors have found that these compounds can be easily prepared as shown in the following reaction scheme. That is to say, 4-halogenated phenols of formula (V) are converted into compounds of formula (VI) which are stable to the base, the halogen group of compound (VI) is substituted with metal such as lithium or magnesium, and then they are converted into the metal thiolate intermediate compounds of formula (VII), using sulfur. The compounds (VII) are reacted with compounds of formula (IV) without separation and purification step, which are prepared from compounds of formula (I) via several steps, to obtain thioether compounds of formula (VIII) easily. It is subjected to deprotecting the phenol residue to get compounds of formula (IX), which are reacted with alkyl halogenated acetate to give compounds of formula (X), and then they are hydrolyzed to have compounds of formula (XI).
    Figure US20070179300A1-20070802-C00003
    Figure US20070179300A1-20070802-C00004

    wherein, R1 represents hydrogen atom, CF3, or halogen atom,
  • n is an integer of 0 to 5,
  • R2 represents a hydrogen atom, fluorine atom, chlorine atom, —(C1-C4) alkyl, —O(C1-C4) alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group,
  • R3 represents a protecting group having a tetrahydropyranyl, —(C1-C4) alkyl, allyl, or silyl group such as alkylsilyl, alkylarylsilyl,
  • R4 represents a —(C1-C4) alkyl group,
  • X1 represents a halogen atom,
  • X2 represents a halogen atom, or leaving group easily displaced by nucleophiles, and
  • M represents a lithium ion or magnesium halide (Cl, Br, or I).
  • An object of the present invention is to provide a process for preparing compounds of formula (XI) in high yield in a short period, via unstable intermediate compounds without separation step in the reaction.
  • The present invention also provides a process for preparing compounds of formula (II), which comprises by reacting compounds of formula (I) with alkyl 2-chloroacetoacetate.
  • The present invention further provides a process for preparing compounds of formula (III), which comprises by reducing the ester group of compounds of formula (II).
  • The present invention further provides a process for preparing compounds of formula (IV), which comprises by introducing a leaving group to compounds of formula (III).
  • The present invention further provides a process for preparing compounds of formula (VI), which comprises by reacting compounds of formula (V) with a phenol protecting group.
  • The present invention further provides a process for preparing compounds of formula (VIII), which comprises by reacting compounds of formula (VI) with metallic or organometallic reagents and sulfur to form compounds of formula (VII), and reacting them with compounds of formula (IV) without a specific organic or inorganic base.
  • The present invention further provides a process for preparing compounds of formula (IX), which comprises by eliminating the protecting group of phenol of compounds of formula (VIII).
  • The present invention further provides a process for preparing compounds of formula (X), which comprises by reacting compounds of formula (IX) with alkyl haloacetate in the presence of organic or inorganic base.
  • The present invention further provides a process for preparing compounds of formula (XI), which comprises by subjecting the ester compounds of formula (X) to hydrolyze.
  • The present invention further provides processes for the novel compounds of formula (VI), (VII), (VIII), and (IX), each of which useful as intermediate compounds for preparation of the final products of the present invention.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • In a process for preparation of compounds of formula (XI) according to the present invention, R1 represents hydrogen atom, CF3, or halogen atom, and the number (n) of the substituent is 0 to 5 of the same or different one.
  • R2 stands for hydrogen atom, fluorine atom, chlorine atom, —O-alkyl, —S-alkyl, or —N-(alkyl)2 (alkyl group having 1 to 4 carbon atoms). The position of each substituent is ortho- or meta- to the phenol group, and the number of substituent is 1 or 2.
  • R3 is a protecting group, and includes a tetrahydropyranyl, alkyl or allyl group having 1 to 4 carbon atoms, or silyl group such as trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl. Preferred examples of the protecting groups among them include tert-butyl, tetrahydropyranyl and silylated groups.
  • R4 is a protecting group, and examples thereof include alkyl having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, n-butyl, and tert-butyl group. Of these, methyl, ethyl, and propyl are preferred.
  • Example of the halogen atom represented by X1 includes a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • X2 represents a leaving group, which can be easily displaced by metal thiolate in nucleophilic substitution reaction.
  • Examples thereof include a halogen atom, methanesulfonate (MsO—), and p-tolunesulfonate (TsO—). Here, the halogen atom means a fluorine atom, chlorine atom, bromine atom or iodine atom.
  • M represents a lithium ion or magnesium halide (Cl, Br, or I).
  • The compounds of the formula (I) and (V) are commercially available or can be synthesized easily by using known methods in the art.
  • The process of the present invention will be described as set below.
  • [Step A] Preparation of Compounds of Formula (II):
  • Compounds of formula (II) can be prepared by reacting compounds of formula (I) with ethyl or methyl 2-chloroacetoacetate in a solvent.
  • Suitable solvents usable in this reaction include alcohols such as methanol, ethanol, propanol, and butanol; and ethers such as diethyl ether, tetrahydrofuran, and 1,4-dioxane. Of these, ethanol or tetrahydrofuran is preferred as a solvent.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct the reaction at 25 to 150° C. for 6 hours to 1 day, more preferably 60 to 120° C. within 16 hours.
  • [Step B] Preparation of Compounds of Formula (III):
  • Compounds of formula (III) can be prepared by reducing the ester moiety of compounds of formula (II) in an anhydrous solvent.
  • As reducing agents, aluminum hydrides such as lithium aluminum hydride, and diiusobutylaluminum hydride, and boron hydrides such as sodium borohydride and lithium borohydride can be given. Among them, lithium aluminum hydride and diissobutylaluminum hydride are preferred.
  • As anhydrous solvents usable in this reaction, diethyl ether, tetrahydrofuran, and dichloromethane can be given, with preferably, dichloromethane.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct the reaction at −100 to 60° C. for 30 minutes to 6 hours, more preferably −78 to 25° C. within 2 hours.
  • [Step C] Preparation of Compounds of Formula (IV):
  • Compounds of formula (IV) can be prepared by subjecting halogenation reaction on compounds of formula (III), or reacting compounds of formula (III) with methanesulfonyl chloride orp-toluene sulfonyl chloride in a solvent.
  • Suitable solvents usable in this include N,N-dimethylformamide, diethyl ether, tetrahydrofuran, tetrachloromethane, chloroform, dichloromethane, and pyridine. Of these, dichloromethane for halogenation reaction, and pyridine for methanesulfonate or p-toluenesulfonate reaction respectively are preferred.
  • Suitable reagents for halogenation reaction to the alcohol moiety include triphenylphosphine (TPP) with N-chlorosuccinimide (NCS), triphenylphosphine with chlorine gas, triphenylphosphine with tetrachloromethane(CCl4), phosphorus pentachloride (PCl5), thionylchloride (SOCl2), and methanesulfonyl chloride (MeSO2Cl) for introduction of chlorine atom; triphenylphosphine with N-bromosuccinimide (NBS), triphenylphosphine with bromine gas, triphenylphosphine with tetrabromomethane (CBr4), phosphorus pentabromide (PBr5), and thionyl bromide (SOBr2) for introduction of bromine atom; triphenylphosphine with N-iodosuccine imide, triphenylphosphine with solid iodine, and triphenylphosphine with tetraiodomethane (CI4) for introduction of iodine atom. Alternatively, introduction of iodine atom can be carried out by substituting chloro- or bromocompounds of formula (IV) with sodium iodide(NaI) in acetone, so-called halogen-iodine substitution method. Of these, the preferred leaving group is chlorine or bromine atom, and the preferred reagent for this reaction is triphenylphosphine with N-chlorosuccinimide or N-bromosuccinimide.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at −10 to 40° C. for 30 minutes to 1 day, more preferably 10 to 25° C. within 2 hours.
  • [Step D] Preparation of Compounds of Formula (VI):
  • Compounds of formula (VI) can be prepared by reacting compounds of formula (V) with conventional compounds for protecting phenol group in the presence of a base in a solvent.
  • Suitable solvents usable in this reaction include N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, acetone, ethyl acetate, tetrachloromethane, chloroform, and dichloromethane as aprotic polar solvents; tetrahydrofuran, 1,4-dioxane, dimethoxy ethane, and diethylene glycol dimethyl ether as ethers; and benzene, toluene, and xylene as aromatic hydrocarbons. Of these, an aprotic polar solvent is preferred, with N, N-dimethylformamide, chloroform, or dichloromethane being particularly preferred.
  • Suitable base usable for reacting silyl protecting group with phenol include amines such as pyridine, triethylamine, imidazole, and N, N-dimethylaminopyridine.
  • Suitable bases usable for reacting aryl ether protecting group with phenol include sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate. As the preferred bases among the above, imidazole and potassium carbonate can be given.
  • Tetrahydropyranyl (THP) protection on the phenol group can be achieved by reacting 3,4-dihydro-2H-pyran with alkyl or aryl triphenylphosphonium bromide.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at −10 to 80° C. for 1 hour to 1 day, more preferably 0 to 25° C. within 4 hours.
  • [Step E] Preparation of Compounds of Formula (VIII):
  • Compounds of formula (VIII) can be prepared by reacting intermediate compounds of formula (VII), without separation, with compounds of formula (IV) in an anhydrous solvent.
  • Suitable anhydrous solvents usable in this reaction include diethyl ether, tetrahydrofuran, hexane, and heptane. These solvents may be used either singly or in combination of two. Diethyl ether, tetrahydrofuran, and a mixed solvent of diethyl ether with tetrahydrofuran are particularly preferred.
  • As suitable metallic reagents used for halogen-metal substitution, lithium metal and magnesium metal can be given, and as organometallic reagents, n-butyllithium, sec-butyllithium, and tert-butyllithium can be used. Of these, organometallic reagents are preferred, with n-butyllithium and tert-butyllithium being particularly preferred.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at −100 to 25° C. for 30 minutes to 1 day, more preferably in the step of sulfur introduction at −78° C., later raising the reaction temperature up to 25° C. for 1 hour after introduction of compounds of formula (IV) into the reaction mixture.
  • [Step F] Preparation of Compounds of Formula (IX):
  • Compounds of formula (IX) can be prepared by eliminating the phenol-protecting group of compounds of formula (VIII) in a solvent.
  • Suitable solvents usable in this reaction include N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, acetone, ethyl acetate, tetrachloromethane, chloroform, and dichloromethane as polar solvents; tetrahydrofuran, 1,4-dioxane, dimethoxy ethane, and diethylene glycol dimethyl ether as ethers; and benzene, toluene, and xylene as aromatic hydrocarbons. Of these, tetrahydrofuran is particularly preferred.
  • Suitable reagents for elimination of the protecting groups of methyl, ethyl, tert-butyl, benzyl, allyl on the phenol group include a Lewis acid such as trimethylsilyliodide, ethane thioalcohol, lithium iodide, aluminum bromide, aluminum chloride, boron triiodide, and trifluoroacetic acid; suitable reagents for elimination of silylated protecting groups such as trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, tert-butyldimethylsilyl include tetrabutylammonium fluoride, hydrochloric acid, hydrobromic acid, hydroiodic acid, and potassium fluoride. Of these, tetrabutylammonium fluoride is preferred for eliminating the silyl-protecting group on the phenol.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at 0 to 120° C. for 30 minutes to 1 day, more preferably 10 to 25° C. within 2 hours. [
  • Step G] Preparation of Compounds of Formula (X):
  • Compounds of formula (X) can be prepared by reacting compounds of formula (IX) with alkyl halogen acetates in the presence of a base in a solvent.
  • The alkyl halogen acetates are commercially available or can be synthesized by known methods in the art. The alkyl group and halogen therein include methyl, ethyl, tert-butyl and a chlorine atom, bromine atom, and iodine atom, respectively. The most preferred one among the alkyl halogen acetates is methyl (or ethyl) chloro (or bromo)acetate.
  • Suitable solvents usable in this reaction include N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, and acetone, with acetone being particularly preferred.
  • There is no specific limitation to bases used regardless of basicity, inasmuch as the base does not affect the reaction. Suitable bases include sodium hydride, lithium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, and potassium bicarbonate. Of these, alkali metal hydride or alkali metal carbonate is preferred, with potassium carbonate being particularly preferred.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at −10 to 120° C. for 30 minutes to 1 day, more preferably 0 to 25 ° C. within 4 hours.
  • [Step H] Preparation of Compounds of Formula (XI):
  • Compounds of formula (XI) can be prepared by subjecting hydrolysis of the carboxylic ester of compounds of formula (X) in the presence of a water-soluble inorganic base and alcohol solvent.
  • Suitable solvents usable in this reaction include methanol, ethanol, and water miscible organic solvents.
  • As a base usable in this reaction, about 0.1 to 6 N aqueous solution of alkali metal hydroxide, such as lithium hydroxide, sodium hydroxide, or potassium hydroxide, is used. Of these, 1 to 3 N sodium hydroxide is preferred.
  • The reaction time and temperature depend on the solvent to be used. However, it is preferred to conduct this reaction at −10 to 80° C. for 10 minutes to 3 hours, more preferably 0 to 25° C. for 30 minutes to 1 hour.
  • Compounds of formula (XI) obtained as above are ligands of the human PPAR protein, PPARδ.
  • EXAMPLES
  • The present invention will next be described in detail by way of examples, which should not be construed as limiting the invention.
  • Example 1 Preparation of methyl 4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole-5-carboxylate [Step A]
  • 4-(Trifluoromethyl)thiobenzamide (20.5 g, 0.1 mol) was dissolved in tetrahydrofuran (300 Ml) at room temperature, and then methyl 2-chloroacetoacetate (12.2 Ml, 0.1 mol) was added slowly for about 20 minutes therein while stirring. After completion of addition, the mixture was stirred again at room temperature for 30 minutes, and then the mixture was heated and refluxed at 78 to 80° C. for 12 hours. After completion of the reaction, the reaction mixture was cooled to room temperature. Subsequently, 50% aqueous solution of sodium hydroxide (150 Ml) was added and stirred for 20 minutes. The resultant organic layer was separated by extraction with ethyl acetate, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure to thereby yield 28.8 g of the title compound (yield: 95.6%).
  • 1H-NMR (300 MHz, CDCl3): 8.01 (d, 2H, J=8.4 Hz), 7.64 (d, 2H, J=8.3 Hz), 3.84 (s, 3H), 2.73 (s, 3H).
  • Example 2 Preparation of [4-methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]-methanol [Step B]:
  • Methyl 4-methyl-2-[4-(trifluoromethyl)phenyl]]thiazole-5-carboxylate (20.0 g, 66.4 mmol) obtained from Example 1 was dissolved in anhydrous dichloromethane (500 Ml) under nitrogen atmosphere, and the reaction mixture was cooled to −78° C. Diisobutyl aluminum hydride (DIBAL-H, 166 Ml, 1.0 M hexane solution, 2.5 eq.) was slowly added to the solution for 30 minutes, and the mixture was reacted for another 30 minutes at the same temperature. Subsequently, the temperature was raised to −10° C. and reacted for 30 minutes. After completion of the reaction, an excessive diisobutyl aluminum hydride was removed by ethyl acetate. The resultant residue was extracted by 10% sulfuric acid and ethyl acetate, followed by drying over magnesium sulfate. The resultant mixture was purified on silica flash column, followed by evaporation under reduced pressure to thereby yield 17.5 g of the title compound (yield: 96.4%).
  • 1H-NMR (300 MHz, CDCl3): 7.94 (d, 2H, J=8.1 Hz), 7.63 (d, 2H, J=8.2 Hz), 4.80 (s, 2H), 2.93 (bs, 1H), 2.41 (s, 3H).
  • 13C-NMR (78.5 MHz, CDCl3): 164.6, 151.0, 137.0, 133.1, 132.0 (q), 126.8, 126.3 (m), 122.5, 57.1, 15.4.
  • Example 3 Preparation of 5-bromomethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step C]:
  • [4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (15.0 g, 55.0 mmol) obtained from Example 2 was dissolved in anhydrous dichloromethane (300 Ml), and then triphenylphosphine (TPP, 5.7 g, 60.0 mmol, 1.1 eq.) and tetrabromomethane (20.0 g, 60.0 mmol, 1.1 eq.) were added to the mixture sequentially at room temperature. After 1 hour, the solvent was evaporated from the reaction mixture under reduced pressure. Subsequently, the remained triphenylphosphine oxide was precipitated by a mixed solvent of hexane and ethyl acetate (v/v=5/1), followed by filtration and evaporation under reduced pressure to thereby yield 17.2 g of the title compound (yield: 93%).
  • 1H-NMR (300 MHz, CDCl3): 8.00 (d, 2H, J=8.1 Hz), 7.67 (d, 2H, J=8.2 Hz), 4.72 (s, 2H), 2.47 (s, 3H).
  • 13C-NMR (78.5 MHz, CDCl3): 165.0, 153.8, 136.9, 132.4, 129.7 (q), 127.0, 126.3 (m), 122.5, 23.8, 15.5.
  • Example 4 Preparation of 5-bromomethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step C]:
  • [4-methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (10.0 g, 36.6 mmol) obtained from Example 2 was dissolved in anhydrous dichloromethane 300 Ml, and then triphenylphosphine (TPP, 10.6 g, 40.3 mmol, 1.1 eq.) and N-bromosuccinimide (7.17 g, 40.3 mmol, 1.1 eq.) were added to the mixture at room temperature. After 1 hour, the solvent was evaporated from the reaction mixture under reduced pressure. Subsequently, the remained triphenylphosphine oxide was precipitated by a mixed solvent of hexane and ethyl acetate (v/v=5/1), followed by filtration and evaporation under reduced pressure to thereby yield 11.1 g of the title compound (yield: 90.5%).
  • Example 5 Preparation of 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step C]:
  • [4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (5.0 g, 18.3 mmol) obtained from Example 2 was dissolved in tetrachloromethane (300 Ml), and then triphenylphosphine (TPP, 6.3 g, 23.8 mmol, 1.3 eq.) was added and the mixture was stirred under reflux for 10 hours. After completion of the reaction, the temperature of the reactor was cooled to room temperature, and a mixed solvent of hexane and ethyl acetate (v/v=5/1) was added thereto to precipitate the remained triphenylphosphine oxide, followed by filtration and evaporation under reduced pressure to thereby yield 8.4 g of the title compound (yield: 78.4%).
  • 1H-NMR (300 MHz, CDCl3): 8.01 (d, 2H, J=8.1 Hz), 7.68 (d, 2H, J=8.2 Hz), 4.79 (s, 2H), 2.51 (s, 3H).
  • Example 6 Preparation of 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step C]:
  • [4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl]methanol (10.0 g, 36.6 mmol) obtained from Example 2 was dissolved in anhydrous dichloromethane (250 Ml) and then triphenylphosphine (TPP, 11.5 g, 44.0 mmol, 1.2 eq.) and N-chlorosuccinimide (5.86 g, 44.0 mmol, 1.2 eq.) were added to the mixture at room temperature. After completion of the reaction, the solvent was evaporated under reduced pressure. Subsequently, the remained triphenylphosphine oxide was precipitated by adding a mixed solvent of hexane and ethyl acetate (v/v=5/1), followed by filtration and evaporation under reduced pressure to thereby yield 10.5 g of the title compound (yield: 98.5%).
  • Example 7 Preparation of 4-iodo-2-methyl-phenoxy-tert-butyldimethyl silane [Step D]:
  • 4-Iodo-2-methylphenol (15.0 g, 64.1 mmol) was dissolved in N, N-dimethylformamide (250 Ml), and imidazole (8.7 g, 128.2 mmol, 2.0 eq.) added to the mixture. tert-Butyldimethyl silyl chloride (10.6 g, 70.5 mmol, 1.1 eq.) was slowly added to the above mixture and stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was extracted with aqueous ammonium chloride solution and ethyl acetate, and dried over magnesium sulfate. The crude product was purified on silica flash column. The solvent was evaporated under reduced pressure to thereby yield 21.8 g of the title compound (yield: 97.5%).
  • 1H-NMR (300 MHz, CDCl3): 7.47 (d, 1H, J=0.6 Hz), 7.35 (dd, 1H, J=8.4, 2.3 Hz), 6.54 (d, 1H, J=8.4 Hz), 2.18 (s, 3H), 1.03 (s, 9H), 0.22 (s, 6H).
  • 13C-NMR (78.5 MHz, CDCl3): 154.3, 139.9, 135.9, 132.3, 121.1, 83.9, 26.2, 18.7, 17.0, −3.8.
  • Example 8 Preparation of ethyl 4-iodo-2-methyl-phenoxyacetate [Step D]:
  • 4-Iodo-2-methylphenol (3.0 g, 12.9 mmol) was dissolved in acetone (250 Ml) at room temperature, and then potassium carbonate (2.67 g, 19.4 mmol, 1.5 eq.) was added thereto and vigorously stirred. Ethyl bromoacetate (1.56 Ml, 14.1 mmol, 1.5 eq.) was quickly added to the mixture, and then reacted further at room temperature for 4 hours. After completion of the reaction, the reaction mixture was extracted with aqueous ammonium chloride solution and ethyl acetate, and dried over magnesium sulfate. The crude product was purified on silica flash column. The solvent was evaporated under reduced pressure to thereby yield 4.26 g of the title compound (yield: 98.5%).
  • 1H-NMR (300 MHz, CDCl3): 7.45 (d, 1H, J=0.6 Hz), 7.39 (dd, 1H, J=8.5, 2.1 Hz), 6.46 (d, 1H, J=8.5 Hz), 2.18 (s, 3H), 4.59 (s, 2H), 4.24 (q, 2H, J=14.3, 7.1 Hz), 2.24 (s, 3H), 1.28 (t, 3H, J=7.1 Hz).
  • 13C-NMR (78.5 MHz, CDCl3): 168.9, 156.3, 139.7, 135.7, 130.4, 113.6, 84.2, 65.9, 61.1, 16.2, 14.4.
  • Example 9 Preparation of 4-bromo-phenoxy-tert-butyldimethyl silane [Step D]:
  • 4-Bromophenol (5.0 g, 29.0 mmol) was dissolved in N,N-dimethylformamide (150 Ml), and imidazole (4.09 g, 60.0 mmol, 2.0 eq.) was added to the mixture. tert-Butyldimethyl silyl chloride (4.36 g, 29.0 mmol, 1.0 eq.) was slowly added to the above mixture and stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was extracted with aqueous ammonium chloride solution and ethyl acetate, and dried over magnesium sulfate. The crude product was purified on silica flash column. The solvent was evaporated under reduced pressure to thereby yield 8.15 g of the title compound (yield: 97.8%).
  • 1H-NMR (300 MHz, CDCl3): 7.32 (d, 2H, J=8.8 Hz), 6.72 (d, 2H, J=10.0 Hz), 0.98 (s, 9H), 0.18 (s, 6H).
  • 13C-NMR (78.5 MHz, CDCl3): 155.3, 132.7, 122.3, 114.0, 26.0, 18.6, −4.1.
  • Example 10 Preparation of 5-[4-(tert-butyldimethylsilanyloxy)-3-methyl-phenylsulfanyl-methyl]-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step E]:
  • 4-Iodo-2-methyl-phenoxy-tert-butyldimethyl silane (5.0 g, 14.4 mmol) obtained from Example 7 was dissolved in anhydrous tetrahydrofuran (200 Ml) under nitrogen atmosphere and cooled to −78° C. tert-Butyllithium (8.47 Ml, 1.7 M hexane solution, 1.0 eq.) was slowly added thereto for 1 minute. The mixture was stirred for 10 minutes, and sulfur powder (460 mg, 14.4 mmol, 1.0 eq.) was poured into the mixture at once at the same temperature. The mixture was stirred for 10 minutes to dissolve the said sulfur completely, and 5-bromomethyl-4-methyl-2-[(4-trifluoro-methyl)phenyl]thiazole (4.84 g , 14.4 mmol, 1.0 eq.) obtained from Example 4 was added at once. The reaction temperature was raised to room temperature slowly for about 1 hour to react, followed by terminating the reaction by aqueous ammonium chloride solution. The reaction mixture was extracted with ethyl acetate and brine. Subsequently, the organic layer was dried over magnesium sulfate and the solvent was evaporated by under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:1) to thereby yield 5.11 g of the title compound (yield: 69%).
  • 1H-NMR (300 MHz, CDCl3): 7.97 (d, 2H, J=8.0 Hz), 7.65 (d, 2H, J=8.2 Hz), 7.17 (d, 1H, J=1.8 Hz), 7.07 (dd, 1H, J=8.2, 2.3 Hz), 6.67 (d, 1H, J =8.3 Hz), 4.10 (s, 2H), 2.20 (s, 3H), 2.15 (s, 3H), 1.00 (s, 9H), 0.20 (s, 6H).
  • 13C-NMR (78.5 MHz, CDCl3): 163.4, 154.9, 151.8, 136.8, 132.6, 130.4, 129.6 (q), 126.8, 126.2 (m), 125.2, 119.6, 33.0, 26.1, 18.7, 17.1, 15.2, −3.9.
  • Example 11 Preparation of 5-[4-(tert-butyldimethylsilanyloxy)-3-methyl-phenylsulfanyl-methyl]-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step E]:
  • 4-Iodo-2-methyl-phenoxy-tert-butyldimethyl silane (5.0 g, 14.4 mmol) obtained from Example 7 was dissolved, while stirring, in anhydrous tetrahydrofuran (150 Ml) and diethyl ether 150 Ml) under nitrogen atmosphere, and was cooled to −78° C. n-Butyl lithium (9.0 Ml, 1.6 M hexane solution, 1.0 eq.) was added thereto for 1 minute. The mixture was stirred for 10 minutes and sulfur powder (460 mg, 14.4 mmol, 1.0 eq.) was poured into the mixture at once at the same temperature. The mixture was stirred for 10 minutes to dissolve the said sulfur completely and 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole (4.14 g, 14.4 mmol, 1.0 eq.) obtained from Example 5 was added at once. The reaction temperature was raised to room temperature slowly for about 1 hour to react, followed by terminating the reaction by aqueous ammonium chloride solution. The reaction mixture was extracted with ethyl acetate and brine. Subsequently, the organic layer was dried over magnesium sulfate and the solvent was evaporated by under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:1) to thereby yield 5.51 g of the title compound (yield: 78.1%).
  • Example 12 Preparation of 5-[4-(tert-butyldimethylsilanyloxy)-phenylsulfanylmethyl]-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole [Step E]:
  • 4-Bromo-phenoxy-tert-butyldimethyl silane (5.0 g, 17.4 mmol) obtained from Example 9 was dissolved in anhydrous tetrahydrofuran (300 Ml) under nitrogen atmosphere and cooled to −78° C. n-Butyl lithium (10.9 Ml, 1.6 M hexane solution, 1.0 eq.) was added thereto for 1 minute. The mixture was stirred for 10 minutes and sulfur powder (557 mg, 17.4 mmol, 1.0 eq.) was poured into the mixture at once at the same temperature. The mixture was stirred for 10 minutes to dissolve the said sulfur completely and 5-chloromethyl-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole (5.08 g, 17.4 mmol, 1.0 eq.) obtained from Example 5 was added at once. The reaction temperature was raised to room temperature slowly for about 1 hour to react, followed by terminating the reaction by aqueous ammonium chloride solution. The reaction mixture was extracted with ethyl acetate and brine. Subsequently, the organic layer was dried over magnesium sulfate, and the solvent was evaporated by under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:1) to thereby yield 7.3 g of the title compound (yield: 84.6%).
  • 1H-NMR (300 MHz, CDCl3): 7.97 (d, 2H, J=8.0 Hz), 7.65 (d, 2H, J=8.2 Hz), 7.24 (d, 2H, J=8.7 Hz), 7.07 (d, 2H, J=10.0 Hz), 4.08 (s, 2H), 2.20 (s, 3H), 2.17 (s, 3H), 0.97 (s, 9H), 0.17 (s, 6H).
  • Example 13 Preparation of 2-methyl-4-{4-methyl-2-[(4-trifluoromethyl)phenyl]-thiazole-5-yl methylsulfanyl}phenol [Step F]:
  • 5-[4-(tert-Butyldimethylsilanyloxy)-3-methyl-phenylsulfanylmethyl]-4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole (5.0 g, 9.8 mmol) obtained from Example 10 was dissolved in tetrahydrofuran (250 Ml). Tetrabutylammonium fluoride (TBAF, 24.5 Ml, 1 M tetrahydrofuran solution, 2.5 eq.) was slowly added at room temperature. After reaction for 30 minutes, the mixture was extracted with aqueous ammonium chloride solution and ethyl acetate, and the organic layer was dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=5:1) to thereby yield 3.67 g of the title compound (yield: 94.6%).
  • 1H-NMR (300 MHz, CDCl3): 7.96 (d, 2H, J=8.2 Hz), 7.64 (d, 2H, J=8.3 Hz), 7.20 (d, 1H, J=1.8 Hz), 6.97 (dd, 1H, J=8.2, 2.2 Hz), 6.59 (d, 1H, J=8.2 Hz), 4.06 (s, 2H), 2.19 (s, 3H), 2.09 (s, 3H).
  • 13C-NMR (78.5 MHz, CDCl3): 163.9, 155.5, 151.7, 137.4, 133.5, 132.0, 131.7, 131.6, 126.8, 126.3 (m), 125.8, 123.8, 115.7, 33.2, 16.2, 14.8.
  • Example 14 Preparation of ethyl {2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl) -thiazole-5-yl sulfanyl]phenoxy}acetate [Step G]:
  • 2-Methyl-4-{4-methyl-2-[(4-trifluoromethyl)phenyl]-thiazole-5-yl methyl-sulfanyl}-phenol (5.0 g, 12.5 mmol) obtained from Example 13 was dissolved in anhydrous tetrahydrofuran (200 Ml), and sodium hydride (378 mg, 15.6 mmol, 1.25 eq.) was added at −10° C. Ethyl bromoacetate (2.1 Ml, 19.0 mmol, 1.5 eq.) was added for 2 hours while stirring vigorously. After completion of reaction, the mixture was extracted with brine and ethyl acetate, and the organic layer was dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified on silica flash column to thereby yield 4.6 g of the title compound (yield: 76.8%).
  • 1H-NMR (300 MHz, CDCl3): 7.97 (d, 2H, J=8.1 Hz), 7.66 (d, 2H, J=8.3 Hz), 7.21 (d, 1H, J=1.7 Hz), 7.12 (dd, 1H, J=8.4, 2.3 Hz), 6.60 (d, 1H, J=8.4 Hz), 4.62 (s, 2H), 4.24 (q, 2H, J=14.3, 7.1 Hz), 2.24 (s, 3H), 2.21 (s, 3H), 1.28 (t, 3H, J=7.1 Hz).
  • 13C-NMR (78.5 MHz, CDCl3): 169.1, 156.8, 151.8, 136.5, 132.5, 131.1, 128.8, 126.8, 126.2 (m), 125.7, 112.0, 66.0, 61.8, 32.9, 16.5, 15.2, 14.5.
  • Example 15 Preparation of ethyl {2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl) -thiazole-5-yl sulfanyl]phenoxy}acetate [Step G]:
  • 2-Methyl-4-{4-methyl-2-[(4-trifluoromethyl)phenyl]thiazole-5-yl methyl-sulfanyl}-phenol (10.0 g, 25.3 mmol) obtained from Example 13 was dissolved in acetone (350 Ml), and potassium carbonate (8.0 g, 58.2 mmol, 2.3 eq.) was added at room temperature. Ethyl bromoacetate (4.2 Ml, 38.0 mmol, 1.5 eq.) was added for 4 hours while stirring vigorously. After completion of reaction, the mixture was extracted with brine and ethyl acetate, and the organic layer was dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified on silica flash column to thereby yield 11.8 g of the title compound (yield: 98.5%).
  • Example 16 Preparation of 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl)sulfanyl]phenoxy}acetic acid [Step H]:
  • Ethyl {2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-yl sulfanyl]-phenoxy}acetate (5.0 g, 10.4 mmol) obtained from Example 15 was dissolved thoroughly in ethanol (300 Ml), and 3 N sodium hydroxide solution (35 Ml) was added. After stirring at room temperature for 30 minutes to complete the reaction, the mixture was adjusted to pH 2.0 with 1 N HCl. The mixture (ca. 80% of ethanol) was evaporated under reduced pressure, and the mixture was extracted with brine and ethyl acetate. The solvent was evaporated under reduced pressure. The residue was dissolved in methanol again and purified by LH-20 column chromatography to thereby yield 4.71 g of the title compound (yield: 98.8%).
  • 1H-NMR (600 MHz, CDCl3): 7.99 (d, 2H, J=8.1 Hz), 7.72 (d, 2H, J=8.3 Hz), 7.17 (s, 1H), 7.14 (dd, 1H, J=8.4, 2.2 Hz), 6.72 (d, 1H, J=8.4 Hz), 4.65 (s, 2H), 4.16 (s, 2H), 2.18 (s, 3H), 2.11 (s, 3H).
  • 13C-NMR (150.9 MHz, CD3OD): 172.7, 164.8, 158.2, 152.6, 138.2, 137.5, 133.8, 133.3, 132.5 (q), 129.4, 127.8, 127.2 (m), 126.2, 112.9, 66.3, 32.9, 16.4, 14.8.
  • INDUSTRIAL APPLICABILITY
  • As described above, compounds of formula (XI) can be prepared in a high yield easily, according to the present invention.

Claims (8)

1-5. (canceled)
6. A compound of formula (XII):
Figure US20070179300A1-20070802-C00005
wherein R1 represents a hydrogen atom, —CF3, or halogen atom;
n is an integer of from 0 to 5;
R2 represents a hydrogen atom, fluorine atom, chlorine atom, —(C1-C4)alkyl, —O(C1-C4)alkyl, —S(C1-C4)alkyl, or —N(C1-C4alkyl)2 group; and
R5 represents a hydrogen atom, or a protecting group having a tetrahydropyranyl, —(C1-C4)alkyl, allyl, or silyl group.
7. A compound of formula (VI), formula (VII), formula (VIII), or formula (IX):
Figure US20070179300A1-20070802-C00006
wherein R2 represents a hydrogen atom, fluorine atom, chlorine atom. —(C1-C4) alkyl, —O(C1-C4)alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group,
R3 represents protecting group having a tetrahydropyranyl, —(C1-C4) alkyl, allyl, or silyl group, and
X1 represents a halogen atom;
Figure US20070179300A1-20070802-C00007
wherein R2 represents a hydrogen atom, fluorine atom, chlorine atom. —(C1-C4) alkyl, —O(C1-C4)alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group,
R3 represents protecting group having a tetrahydropyranyl, —(C1-C4) alkyl, allyl, or silyl group,
M represents a lithium ion or magnesium chloride, magnesium bromide, or magnesium iodide;
Figure US20070179300A1-20070802-C00008
wherein R1 represents hydrogen atom, CF3, or halogen atom, n is an integer of 0 to 5,
R2 represents a hydrogen atom, fluorine atom, chlorine atom. —(C1-C4) alkyl, —O(C1-C4)alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group,
R3 represents protecting group having a tetrahydropyranyl, —(C1-C4) alkyl, allyl, or silyl group; or
Figure US20070179300A1-20070802-C00009
wherein R1 represents hydrogen atom, CF3, or halogen atom, n is an integer of 0 to 5, R2 represents a hydrogen atom, fluorine atom, chlorine atom, —(C1-C4) alkyl, —O(C1-C4)alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group.
8. A process for preparing a compound of formula (VIII) which comprises reacting a compound of formula (VII) with a compound of formula (IV) to form a compound of formula (VIII)
Figure US20070179300A1-20070802-C00010
wherein R1 represents a hydrogen atom, CF3, or halogen atom, n is an integer of 0 to 5, R2 represents a hydrogen atom, fluorine atom, chlorine atom, —(C1-C4) alkyl, —O(C1-C4)alkyl, —S(C1-C4) alkyl, or —N(C1-C4 alkyl)2 group,
R3 represents a protecting group having a tetrahydropyranyl, —(C1-C4) alkyl, allyl, or silyl group
R4 represents a —(C4) alkyl group,
X1 represents a halogen atom,
X2 represents a halogen atom or leaving group which can be displaced by nucleophiles, and
M represents a lithium ion or magnesium chloride, magnesium bromide or magnesium iodide.
9. A process for preparing a compound of formula (IX) which comprises the process according to claim 8 and further comprises eliminating the protecting group of a compound of formula (VIII) to obtain a compound of formula (IX)
Figure US20070179300A1-20070802-C00011
10. A process for preparing a compound of formula (X) which comprises the process according to claim 9 and further comprises reacting a compound of formula (IX) with alkyl halogenated acetate to produce a compound of formula (X)
Figure US20070179300A1-20070802-C00012
11. A process of preparing a compound of formula (XI) as defined in claim 7 which comprises eliminating the protecting group of a compound of formula (VIII) to obtain a compound of formula (IX), reacting the compound of formula (IX) with alkyl halogenated acetate to produce a compound of formula (X), and hydrolyzing a compound of formula (X) to produce a compound of formula (XI)
Figure US20070179300A1-20070802-C00013
12. A process of preparing a compound of formula (XI) as defined in claim 7 which comprises reacting a compound of formula (IX) with alkyl halogenated acetate to produce a compound of formula (X), and hydrolyzing the compound of formula (X) to produce a compound of formula (XI)
Figure US20070179300A1-20070802-C00014
US11/730,658 2002-05-04 2007-04-03 Process for preparing thiazole derivative and the intermediate compounds for preparing the same Abandoned US20070179300A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/730,658 US20070179300A1 (en) 2002-05-04 2007-04-03 Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2002-0024595A KR100474202B1 (en) 2002-05-04 2002-05-04 Process for preparing thiazol derivative and the intermediate compounds for preparing the same
KR2002-0024595 2002-05-04
US10/513,408 US7241901B2 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same
PCT/KR2003/000877 WO2003106442A1 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same
US11/730,658 US20070179300A1 (en) 2002-05-04 2007-04-03 Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2003/000877 Division WO2003106442A1 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same
US10/513,408 Division US7241901B2 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Publications (1)

Publication Number Publication Date
US20070179300A1 true US20070179300A1 (en) 2007-08-02

Family

ID=29728605

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/513,408 Expired - Lifetime US7241901B2 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same
US11/730,658 Abandoned US20070179300A1 (en) 2002-05-04 2007-04-03 Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/513,408 Expired - Lifetime US7241901B2 (en) 2002-05-04 2003-05-01 Process for preparing thiazole derivative and the intermediate compounds for preparing the same

Country Status (8)

Country Link
US (2) US7241901B2 (en)
EP (1) EP1501811B1 (en)
JP (1) JP2005536480A (en)
KR (1) KR100474202B1 (en)
CN (1) CN100457744C (en)
DE (1) DE60328376D1 (en)
ES (1) ES2330095T3 (en)
WO (1) WO2003106442A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598821C (en) * 2004-12-31 2011-05-31 Heonjoong Kang Organoselenium containing compounds and their use
ATE539066T1 (en) * 2004-12-31 2012-01-15 Seoul Nat Univ Ind Foundation COMPOUNDS CONTAINING ORGANOSELS AND THEIR USE
KR100797798B1 (en) * 2005-02-25 2008-01-24 재단법인서울대학교산학협력재단 Thiazole derivatives as ppar? ligands and their manufacturing process
WO2006091047A1 (en) * 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
CN101193876B (en) * 2005-05-07 2011-05-11 财团法人首尔大学校产学协力财团 Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
WO2007127502A2 (en) * 2006-01-10 2007-11-08 Smithkline Beecham Corporation Polymorphic form of { 2-methyl-4- [ 4-methyl-2- ( 4-triflu0r0methylphenyl) thiazol -5- ylmethylthiol phenoxy }-acetic acid
KR101005020B1 (en) 2006-12-13 2010-12-30 대전대학교 산학협력단 Novel coumarin derivatives and the composition comprising the same showing anti-inflammatory and anti-allergy activity
RU2444518C2 (en) 2007-01-08 2012-03-10 Сеул Нэшнл Юниверсити Индастри Фаундейшн THIAZOLE DERIVATIVE AS PPARδ LIGAND AND PHARMACEUTICAL, COSMETICAL AND DIETARY FOOD CONTAINING IT
CN107879994A (en) * 2017-10-31 2018-04-06 广西师范大学 A kind of synthetic method of thiazole compound
CN109897013B (en) * 2019-03-31 2023-04-07 无锡科华生物科技有限公司 Preparation method of selective PPAR delta agonist GW501516

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498174B1 (en) * 1998-08-07 2002-12-24 Smithkline Beecham Corporation Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators
US20050159598A1 (en) * 2002-02-28 2005-07-21 Kenneth Ingold Process for preparation of chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727187A (en) * 1984-06-15 1988-02-23 Ciba-Geigy Corporation Process for the preparation of α, α-difluoroalkyl phenyl ether derivatives
JPH06306005A (en) * 1993-04-23 1994-11-01 Nippon Kayaku Co Ltd Ether compound and production thereof
CN1233241A (en) * 1996-08-19 1999-10-27 日本烟草产业株式会社 Propionic acid derivatives and applications thereof
KR100620337B1 (en) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (en) * 1999-12-02 2001-10-18 Glaxo Group Ltd OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR
JP2001354671A (en) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta
US6787552B2 (en) * 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
JP2004517100A (en) 2000-12-20 2004-06-10 グラクソ グループ リミテッド Substituted oxazoles and thiazoles as hPPARalpha agonists
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498174B1 (en) * 1998-08-07 2002-12-24 Smithkline Beecham Corporation Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators
US20050159598A1 (en) * 2002-02-28 2005-07-21 Kenneth Ingold Process for preparation of chemical compounds

Also Published As

Publication number Publication date
EP1501811B1 (en) 2009-07-15
CN100457744C (en) 2009-02-04
JP2005536480A (en) 2005-12-02
ES2330095T3 (en) 2009-12-04
US7241901B2 (en) 2007-07-10
WO2003106442A1 (en) 2003-12-24
EP1501811A4 (en) 2006-02-08
KR20030086373A (en) 2003-11-10
DE60328376D1 (en) 2009-08-27
EP1501811A1 (en) 2005-02-02
CN1649854A (en) 2005-08-03
KR100474202B1 (en) 2005-03-08
US20050176785A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US20070179300A1 (en) Process for preparing thiazole derivative and the intermediate compounds for preparing the same
CZ287693A3 (en) Thiazolidinedione derivatives, process for preparing and use
US20180186753A1 (en) Processes for the preparation of pesticidal compounds
CN101489998B (en) Process for producing 2-hydroxy-4-(methylthio)butyric acid or ester and intermediate thereof
KR100797798B1 (en) Thiazole derivatives as ppar? ligands and their manufacturing process
US7982050B2 (en) Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
WO2006091047A1 (en) Thiazole derivatives as ppar delta ligands and their manufacturing process
KR100691375B1 (en) Process for preparing ligands of ppar? and the intermediate compounds for preparing the same
US7429675B2 (en) Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
KR100632872B1 (en) PROCESS FOR PREPARING LIGANDS OF PPARδ AND THE INTERMEDIATE COMPOUNDS FOR PREPARING THE SAME
CN101830863B (en) Method and intermediate compound for preparing ligand of PPAR (Peroxisome Proliferator-Activated Receptor) delta
KR100723828B1 (en) Process for alkyl aryl sulfide derivatives and new sulfide compounds
EP2064219A2 (en) Aromatic sulfinates and sulfonyl halides, and the preparation thereof
JPH0480910B2 (en)
JP3697502B2 (en) Tri-lower alkylsilylethyl sulfide compound and process for producing the same
KR20000075700A (en) Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid derivatives
US20220106273A1 (en) Pyridone compound production method
JPS63119454A (en) Novel alpha-chloroketone derivative and production thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION, KOR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KANG, HEONJOONG;HAM, JUNGYEOB;REEL/FRAME:020072/0001;SIGNING DATES FROM 20071010 TO 20071011

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION